An effective blood-based method for the diagnosis and prognosis of hepatocellular
carcinoma (HCC) has not yet been developed. Circulating tumour DNA (ctDNA) carrying …

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and has a
poor prognosis. Epigenetic modification has been shown to be deregulated during HCC …

Circulating tumor DNA (ctDNA) has emerged as a useful diagnostic and prognostic
biomarker in many cancers. Here, we conducted a study to investigate the potential use of …

Background Aberrant DNA methylation may offer opportunities in revolutionizing cancer
screening and diagnosis. We sought to identify a non-invasive DNA methylation-based …

Background & Aims Hepatocellular carcinoma (HCC) can be treated effectively if detected at
an early stage. Recommended surveillance strategies for at-risk patients include ultrasound …

Alterations in DNA methylation frequently occur in hepatocellular cancer (HCC). We have
previously demonstrated that hypermethylation in candidate genes can be detected in …

Abstract BACKGROUND Circulating tumor DNA (ctDNA) has emerged as a good candidate
for tracking tumor dynamics in different cancer types, potentially avoiding repeated tumor …

Background Targeted methylation sequencing of plasma cell-free DNA (cfDNA) has a
potential to expand liquid biopsies to patients with tumors without detectable oncogenic …

Cell-free DNA (cfDNA)–based liquid biopsy is a promising approach for the early detection
of cancer. A major hurdle is the limited yield of cfDNA from one blood draw, limiting the use …

Hepatocellular carcinoma (HCC), the most prevalent form of liver cancer, is growing in
incidence but treatment options remain limited, particularly for late stage disease. As liver …